<DOC>
	<DOCNO>NCT00447967</DOCNO>
	<brief_summary>This phase II trial compare efficacy toxicity combination Irinotecan Oxaliplatin versus 5-FU/LV Oxaliplatin first line treatment patient locally advance metastatic gastric cancer</brief_summary>
	<brief_title>Combination CPT-11 LoHP v Combination 5-FU , Leucovorin LoHP 1st Line Treatment Gastric Patients</brief_title>
	<detailed_description>There regimen consider standard advanced gastric cancer . The reported response rate 5-FU-based combination chemotherapy high single agent ( 10-50 % ) toxic . The combination 5-FU/LV LOHP demonstrate ORR 43 % , median TTP approximately 6,5 month OS 8,6 month phase II trial , acceptable toxicity . Irinotecan ( CPT-11 ) effective salvage treatment metastatic gastric cancer synergistic activity LOHP preclinical trial</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic gastric cancer . Measurable evaluable disease . Measurable disease define least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique 1 bidimensionally measurable lesion ≥ 20 X 10 mm . Lesions small uni bidimensionally unmeasurable consider evaluable disease . Previous adjuvant chemotherapy Irinotecan , Oxaliplatin and/or 5FU base regimen . Patients relapse within first 6 month completion adjuvant treatment eligible study . Karnofsky performance status &gt; 70 % . Age ≥18 year . Adequate liver ( Bilirubin ≤ 1.5 UNL , SGOT/SGPT ≤ 4 UNL , ALP ≤ 2.5 UNL ) , renal ( Creatinine ≤ 1.5 UNL ) bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥ 100,000/mm3 ) function . Patients must able understand nature study give write informed consent . Active infection History serious cardiac disease ( unstable angina , congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) Previous radiotherapy within last 4 week &gt; 25 % bone marrow . Patients CNS metastasis Patients chronic diarrhea ( least 3 month ) partial bowel obstruction . Malnutrition loss &gt; 10 % body weight last month . Peripheral neuropathy ≥ grade 2 Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer . Psychiatric illness social situation would preclude study compliance . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Metastatic Gastric Cancer</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Irinotecan</keyword>
</DOC>